JANX Q3 2024 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$439,000-82.6% YoY

Gross Profit

$439,000100.0% margin

Operating Income

-$36M-8164.5% margin

Net Income

-$28M-6391.6% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

-95.1%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$695M

Total Liabilities

$39M

Stockholders' Equity

$656M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$439,000	$3M	-82.6%
Gross Profit	$439,000	$2M	-78.2%
Operating Income	-$36M	-$16M	-126.7%
Net Income	-$28M	-$12M	-142.6%